This is an old revision of this page, as edited by Beetstra (talk | contribs) at 11:32, 24 October 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 11:32, 24 October 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Clinical data | |
|---|---|
| Trade names | Eminase |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 90 minutes |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | approx. 131,000 g/mol |
| (verify) | |
Anistreplase is a thrombolytic drug.
Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)
Mechanism
It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.
References
- Rawles J (1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". BMJ. 312 (7025): 212–5. PMC 2350007. PMID 8563585.
{{cite journal}}: Unknown parameter|month=ignored (help) - Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C (1995). "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 (393): 175–9. PMC 1239197. PMID 7612317.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Rawles J, Light J (1993). "Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377–381. doi:10.1136/jech.47.5.377. PMC 1059832. PMID 8289038.
{{cite journal}}: Unknown parameter|month=ignored (help)
| Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiplatelet drugs |
| ||||||||||||||
| Anticoagulants |
| ||||||||||||||
| Thrombolytic drugs/ fibrinolytics | |||||||||||||||
| Non-medicinal | |||||||||||||||
| |||||||||||||||
 | This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it. |